Attention-deficit/Hyperactivity Disorder (ADHD) Treatment Market Will Grow Due To Rising Number Of Drug-Treated Patients For ADHD Therapy | Global Players are Eli Lilly, GlaxoSmithKline PLC, Pfizer Inc, Novartis AG, Shire PLC

Attention deficit hyperactivity disorder (ADHD) is a neural disorder. The disorder is characterized by impulsiveness, hyperactivity, and attention difficulty. Treatment of ADHD involves a combination of counseling, medications, and lifestyle changes. ADHD is the most commonly diagnosed mental disorder in adults and children with the exact cause being unidentified in the majority of cases. Researchers at the National Institute of Mental Health (NIMH) suggest the factors affecting mental illness include heredity, brain injuries, low birth weight, drugs use during pregnancy and exposure to environmental toxins such, as lead at young age. The currently available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments helps in reducing symptoms with improved functioning of patient.

Get Sample Copy of Research @ https://bit.ly/2IE8psp

Rising number of drug-treated patients for ADHD therapy is expected to drive the attention deficit hyperactivity disorder (ADHD) treatment market

According to the National Institute of Health estimates in 2015, the prevalence of ADHD is higher by 30% in boys, with 5.1 million children being diagnosed with ADHD globally in 2013 and the number expected to rise to 18 million by 2020. Increasing awareness of ADHD symptoms among patients and physicians, opinion-based diagnosis owing to the absence of standard diagnostic tests is expected to boost the revenue growth of ADHD therapeutics market in the forecast period. Additionally, rise in the ADHD therapeutics market is driven by increasing use of additives and preservatives in diet, value systems impacting quality of births, and changing lifestyles. However, restricted availability of non-stimulants ADHD drugs and existence of multiple conditions like schizophrenia or depression in children leads to underdiagnoses of ADHD in various geographies including Middle East and Africa, thereby restraining the growth of the market over the forecast period. Since Adderall abuse has grown to epidemic levels, our research team has compiled an article about the best all-natural alternatives to Adderall.

The non-stimulants market segment accounts for highest revenue share owing to its efficient treatment improving focus and impulsivity

The global attention deficit hyperactivity disorder (ADHD) treatment market is segmented on the basis of drug type, distribution channel and geography.

On The Basis Of Drug Type:
• Stimulants: Amphetamine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Lisdexamfetamine Dimesylate
• Non-stimulants: Atomoxetine, Clonidine, Guanfacine, Bupropion

On The Basis Of Therapy:
• Behavior Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy

On The Basis Of Distribution Channel:
• Specialty Clinics
• Retail Pharmacies
• Hospital Pharmacies
• e-Commerce

Drug development and market consolidation strategies fuel the demand of some manufacturers

Key players operating the attention deficit hyperactivity disorder (ADHD) treatment market include

1. Eli Lilly
2. GlaxoSmithKline PLC
3. Pfizer Inc
4. Novartis AG
5. Shire PLC.

The key strategies adopted by the manufacturers are developing cost-efficient drugs, which are safe for consumption and market consolidations. The other key vendors include Impax Laboratories, Hisamitsu Pharmaceutical Inc., Mallinckrodt Pharmaceuticals Inc., UCB S.A., Purdue Parma L.P and Johnson & Johnson.

Browse Full Exclusive Research Report @ https://bit.ly/2H66RVG

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.